Synovics Pharmaceuticals, Inc. (SYVC)

0.0001 0.0000 (0.00%) At close: 02:10PM EDT

Synovics Pharmaceuticals, Inc.

5360 Northwest 35th Avenue
Fort Lauderdale, FL 33309
United States
954-486-4590

Sector(s): 
Industry: 
Full-time employees: 155

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jyotindra R. Gange	Interim Principal Executive Officer & Director	N/A	N/A	1949
Mr. John R. Palmer	Chairman of InCon Technologies Inc.& Incon International Ltd. & CEO of InCon Technologies Inc	N/A	N/A	1943

Amounts are as of 31 December 2008, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Synovics Pharmaceuticals, Inc., through its subsidiaries, engages in the development, manufacture, and commercialization of generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States. The company's OTC product categories include analgesics, cough, cold, antihistamines, asthma relief, and laxatives. It packages and distributes its products to chain drug stores, wholesalers, and distributors in the United States. The company was formerly known as Bionutrics Inc. and changed its name to Synovics Pharmaceuticals, Inc. in 2006. Synovics Pharmaceuticals, Inc. was founded in 1983 and is based in Fort Lauderdale, Florida. Synovics Pharmaceuticals, Inc. operates as a subsidiary of Maneesh Pharmaceuticals Limited.

Corporate governance

Synovics Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.